Cited 60 times in
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.